Figure 2.

WMH volume in different diagnostic groups. (A) Participants were grouped by clinical diagnosis (n = 1803; see Supplementary Table S1). (B) Participants were grouped by clinical diagnosis and CSF-determined Aβ status (n = 1,182; see Supplementary Table S2). (C) Participants were grouped by clinical diagnosis and CSF-determined p-tau status (n = 1,182; see Supplementary Table S3). (D) Participants were grouped by clinical diagnosis and CSF-determined Aβ and p-tau statuses (n = 1,182; see Supplementary Table S4). According to a previous standard, we set the cutoff value at 977 pg./mL for Aβ and 27 pg./mL for p-tau to select participants with Aβ deposition (< 977 pg./mL; A+) and fibrillar tau (> 27 pg./mL; T+). The WMH volume was total intracranial volume-normalized and log-transformed (Supplementary Figure S2 shows the distribution of original WMH values and log-transformed WMH values). The results are presented in improved box charts; the red lines indicate the median values; the upper straight lines indicate the upper quartiles and the lower straight lines indicate the lower quartiles. Statistical analysis was conducted using one-way ANOVA followed by Tukey’s test (adjusted p value). Comparisons among groups: *, < 0.05; **, < 0.01; ***, < 0.001; #, > 0.05. WMH, white matter hyperintensity; NC, cognitively normal control; MCI, mild cognitive impairment; CSF, cerebrospinal fluid; Aβ, β-amyloid; p-tau, phosphorylated tau; ANOVA, analysis of variance.